North America
Tags: Canada, Life SciencesBy Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin
Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …
Read or download the full article below.
Latest Updates
Related Articles
Related Articles by Jurisdiction
Canada: Donald Trump, Paris and the Climate Policy Two-Step
Will the U.S. withdrawal from the Paris Agreement fundamentally alter Canada's course?
UK FCA consults on requirements for reports on payments to government
While Canada does not currently have a reporting regime for payments to governments, a process is underway to ensure that a regime is implemented in the near future.
Drastic changes in the US immigration landscape
The landscape is undergoing drastic changes that all companies and their employees need to understand.
Latest Articles
